Amarin gains 315% after data link triglycerides with CV risk

Amarin Corp. plc. (NASDAQ:AMRN) jumped $9.41 (315%) to $12.40 on Monday after top-line data from the Phase III REDUCE-IT trial showed that once-daily 4 g Vascepa icosapent ethyl led to a 25% reduction in major adverse cardiovascular events (MACE) vs. placebo, meeting the primary endpoint (p<0.001).

A lack of definitive data relating triglyceride lowering to CV protection has prevented physicians from prescribing Vascepa to at-risk patients, but Amarin hopes Monday's data will remove physicians' hesitations. Additional data will be presented Nov. 10 at the American Heart Association meeting in Chicago, and the company expects to submit an sNDA to FDA early next year...